In recent years, much progress has been made in the field of cervical cancer prevention and treatment. However, the occurrence of the two main protagonists of cervical cancer – cervical squamous cell carcinoma and cervical adenocarcinoma – and some of the details faced in the treatment of the disease still need further clinical exploration and research. The proportion of adenocarcinoma is increasing Whether it is squamous or adenocarcinoma, the causative factor is infection with high-risk HPV viruses. more than 120 subtypes of the HPV virus family are known. Thirteen or fourteen of them, are high-risk types. Adenocarcinoma is more likely to be infected with HPV subtype 18; squamous carcinoma is primarily infected with HPV subtype 16. ”The increased proportion of adenocarcinomas also places new demands on treatment.” As a reminder: 1. squamous cervical cancer is mainly by lymphatic metastasis route; adenocarcinoma is more often by blood-borne metastasis; 2. the incidence of ovarian metastasis is higher in cervical adenocarcinoma than in squamous cervical cancer; 3. adenocarcinoma is more likely to have lymph node metastasis than squamous cancer, and the larger the tumor, the more likely it is to have lymph node metastasis; 4. the biological characteristics of adenocarcinoma and squamous cancer are different, and the patterns of metastasis and recurrence are also different, with adenocarcinoma having The rate of metastasis is higher; compared to squamous carcinoma of the cervix, adenocarcinoma of the cervix has the biological behavioral characteristics of being more likely to metastasize to the abdominal cavity and parietal aortic lymph nodes. Therefore, the role of chemotherapy should be enhanced. In general, the number of chemotherapy courses should be more for adenocarcinoma than for squamous carcinoma.